Shots:

• The P-III CANDOR study involves assessing of KYPROLIS (56 mg/m²) + dexamethasone + DARZALEX vs KYPROLIS and dexamethasone monothx in 466 relapsed or refractory multiple myeloma patients who have received one to three prior therapies
• P-III CANDOR study results: met its 1EPs of PFS- 37% reduction in the risk of disease progression or death in patients; mPFS was not reached in KdD vs 15.8 mos. @Kd; ORR (84.3% vs 74.7%); CR (28.5% vs 10.4%); MDR- @12 mos.CR (12.5% vs 1.3%); mOS not reached; will be presented at 61^st ASH
• KYPROLIS (carfilzomib) has the capability to block proteasomes and can also cause cell death especially in myeloma cells and is approved in multiple areas including the US- Japan- Canada and EU. The P-III CANDOR study is initiated in a collaboration with Janssen and co-fund the trial

Click here to­ read full press release/ article | Ref: Amgen | Image: Twitter